Effect of calcium lactate supplementation on cholesterol concentration in patients with hyperlipidaemia and previous viral hepatitis: a preliminary report

G ANDRYSKOWSKI, J CHOJNOWSKA-JEZIERSKA, M BRONCEL, M BARYLSKI, M BANACH

Summary
The aim of the study was to estimate the effect of calcium supplementation on cholesterol concentrations in patients with hyperlipidaemia and previous viral hepatitis. The study comprised 43 patients, aged 28 to 82 years (21 with type 2 hyperlipidaemia). The control group included 22 healthy subjects. After four weeks of a hypolipaemic diet (wash-out period), the patients with type 2 hyperlipidaemia were recruited to a group administered a complex preparation containing 170 mg of calcium lactate and 60 mg of vitamin C (Calcium C, Polfa-Lodz SA, Poland) at a dose of one tablet three times a day.

After four weeks of active therapy, the concentration of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) decreased by 4, 6 and 8%, respectively. Statistical significance was obtained for only TC ($p = 0.03$) when comparing the group of patients with hypercholesterolaemia before and after the therapy with the calcium preparation. A statistically insignificant increase of high-density lipoprotein cholesterol (HDL-C) of 1% was observed. Within the four-week period of therapy, the total concentration of calcium decreased by 3%, whereas the concentration of ionised calcium increased by 7%. None of the obtained values was of statistical significance.

In patients with type 2 hyperlipidaemia and previous viral hepatitis, a four-week supplementation of calcium in a calcium lactate preparation beneficially modified the lipid profile. It statistically significantly decreased the total cholesterol concentration by 4% ($p = 0.03$), did not cause any significant changes in serum calcium concentration, was well tolerated and did not induce any side effects.

Department of Internal Diseases and Cardiological Rehabilitation, Medical University of Lodz, Poland
M BARYLSKI, MD PhD

Department of Internal Diseases and Clinical Pharmacology and Monitored Therapy, Medical University of Lodz, Poland
G ANDRYSKOWSKI, MD, PhD
J CHOJNOWSKA-JEZIERSKA, MD
M BRONCEL, MD PhD

Department of Cardiology, Medical University of Lodz, Poland
M BANACH, MD, PhD, FASA, MAHA; maciejbanach@ad.co.uk

Among patients with hyperlipidaemia who qualified for treatment with statins, there were some who had viral hepatitis in their history. Statins are metabolised by the liver, mainly by isoenzyme CYP3A4.1 Active liver disease and a three-fold increase in the activity of aminotransferases above the upper limit of the norm during the course of the therapy was a contraindication for statin therapy. However, slight elevation of the activity of aminotransferases did not disqualify the patients with a history of viral hepatitis from statin therapy, since available data showed a lack of correlation between hepatotoxicity and earlier viral infection of the liver. Gipson et al. administered statins to patients with chronic hepatitis C and they did not find any increase in aminotransferases.2 However, despite the lack of absolute contraindications for statin therapy in patients with a history of liver disease, doctors are often anxious about the safety of the therapy and eagerly use alternative methods of treatment.

Decrease in total cholesterol concentrations in rats, rabbits and goats after calcium supplementation in the form of oral administration of different calcium compounds was reported in a few published experimental studies.4-9 Also in a few clinical studies, beneficial modification of lipid profiles was observed after long-term supplementation with calcium preparations.10-15

In the Polish population, calcium supply is generally lower than that required by nutritional standards and hence its supplementation is recommended.16 Calcium is not metabolised in the liver and therapy with calcium preparations is safe and devoid of any side effects.

The aim of the study was to estimate the effect of calcium supplementation on cholesterol concentration in patients with hyperlipidaemia and previous viral hepatitis B.

Material and methods
The study comprised 43 patients (22 women, 21 men), aged 28 to 82 years (53.5 ± 9.25). In this group, 21 patients (nine women, aged 52.9 ± 14.92 years; 12 men, aged 48 ± 9.96 years) had a history of viral hepatitis B and at the time of the study they manifested type 2 hyperlipidaemia according to Fredrickson.17
Hyperlipidaemia was diagnosed on the basis of laboratory tests the patients had on admission to the hospital and then again at our department for confirmation.

Initial concentrations of TC > 200 mg/dl (5.2 mmol/l), LDL-C > 145 mg/dl (3.75 mmol/l) and TG < 400 mg/dl (4.54 mmol/l) were the criteria for inclusion into the patient group. The control group included 22 healthy subjects (nine men; 13 women, aged 56.9 ± 6.3 years) with normal lipid values. Patients with other types of hyperlipidaemia, with obesity (BMI > 30 kg/m²), and renal and liver failure were excluded from the study.

There were no smokers, people abusing alcohol, or taking anticoagulants, cardiac glycosides or hypolipaemic drugs among the tested patients. Seven patients (four women and three men) had a diagnosed mild hypertension (stage 1 according to WHO) and they were taking one drug on a regular basis (indapamide, perindopril, lisinopril, enalapril, potassium losartan or nitrendipine). During subsequent follow up, the blood pressure values were in the normal range.

The study schedule included a four-week diet limiting the fat content (wash-out period) prior to the examination. In patients in whom the values of TC, LDL-C and TG exceeded the given reference ranges, the treatment was introduced with a complex preparation containing 170 mg calcium lactate and 60 mg vitamin C (Calcium C, Polfa-Lodz SA, Poland) in the form of effervescent tablets. The recommended dose was one tablet three times daily with meals. Active supplementation lasted four weeks.

The examined subjects were allocated into two groups: group 1: 21 patients with a history of viral hepatitis B and type 2 hyperlipidaemia (nine women and 12 men), aged 50.4 ± 14.9 years; control group 2: 22 healthy subjects (nine men and 13 women) with normal lipid concentrations, aged 56.90 ± 6.3 years.

Fasting blood was collected from a cubital vein (at least 14 h after the last meal). The determination was performed prior to the examination and after four weeks of therapy. In the control group, the tests were carried out once during periodic medical examinations. A lipid profile was done and the concentration of total and ionised calcium was determined in each examined subject.

Biochemical investigations were done on a Cobas Integra 800, Hitachi (Switzerland) using Roche kits. TC, LDL-C, HDL-C and TG were determined by enzymatic methods with Elecsys 2010 (Japan) and Roche kits. LDL-C concentrations were calculated according to Friedwald's formula.

Approval of the Medical University of Lodz Ethics Committee for Scientific Research was received for this study (No RNN30/05/KB). Written, informed consent from each patient was obtained before the study.

For statistical analysis, Smirnow's test was used to assess the distribution of variables. When the distribution of the investigated ranks was in accordance with a normal distribution, the Student's t-test was applied. When the distribution of ranks was not in accordance with a normal distribution, the Wilkoxon's test for matched pairs and Mann-Whitney U-test for unrelated pairs were used.

Results

After four weeks of active therapy with the calcium lactate preparation, the concentration of TC, LDL-C and TG decreased by 4, 6 and 8%, respectively. Statistical significance was obtained for only TC (p = 0.03) when comparing the group of patients with hypercholesterolaemia before and after the therapy. The other lipid fractions (LDL-C and TG) did not demonstrate any statistical significance. Statistically insignificant increases of HDL-C of 1% (p > 0.05) were observed. Within the four-week calcium-supplementation period (total dose of 510 mg/24 h), total calcium concentrations decreased by 3%, whereas the concentration of ionised calcium increased by 7%. None of the obtained values was of statistical significance. The detailed results are shown in Fig. 1 and Tables 1–3.

The activity of aminotransferases was determined in all the examined patients before the introduction of the therapy. In four patients with a history of viral hepatitis B, the values of ALAT and AST were elevated insignificantly. They did not exceed twice the upper normal limit in any case. No statistically significant difference was observed in the activity of aminotransferases in patients before and after the therapy with the calcium preparation.

Discussion

In the available literature, a few clinical studies have been described in which a decrease in cholesterol level or its fraction

<table>
<thead>
<tr>
<th>TABLE 1. CHARACTERISTICS OF PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigated group (n = 21)</td>
</tr>
<tr>
<td>Control group (n = 22)</td>
</tr>
<tr>
<td>Parameters</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
</tr>
<tr>
<td>Number of current smokers</td>
</tr>
<tr>
<td>Hypertension women</td>
</tr>
<tr>
<td>Hypertension men</td>
</tr>
<tr>
<td>Arterial pressure (mmHg)</td>
</tr>
<tr>
<td>Transaminases activity (U/l)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Urea (mg/dl)</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
</tr>
</tbody>
</table>

Fig. 1. Comparison of changes in percentage of lipid values and total and ionised calcium concentration in patients treated with calcium preparation, in relation to initial values before the therapy (p = 0.03 statistical comparison).
Lactate. The effectiveness of this preparation probably resulted from good solubility of calcium lactate in aqueous medium, and the increased bioavailability of vitamin C found in the preparation.14

The mechanism of the effect of calcium on the concentration of cholesterol and its fractions in blood serum is little known. In the alimentary tract, calcium probably binds with bile acids and the cholesterol contained in food. This causes precipitation of insoluble salts, which are not absorbed from the alimentary tract into the blood stream, and are excreted. Increased cholesterol catabolism may cause induction of the LDL receptor. During the four-week therapy with calcium lactate, no side effects were reported, no disorders were found in renal efficiency (creatinine, urea) or liver function (ALAT, AspAT).15,16

Due to the small number of patients, the short period of treatment and the relatively low dose of calcium lactate, the presented outcomes should be considered as a preliminary study. Further studies (being continued by the authors) are necessary to confirm the role of calcium lactate preparation in this selected group of patients.

Conclusion

In patients with type 2 hyperlipidaemia and a history of viral hepatitis, a four-week calcium lactate supplementation: (1) beneficially modified lipid profiles – decreased total cholesterol by 4% \((p = 0.03); (2) did not cause significant changes in serum calcium concentrations; and (3) was well tolerated and did not induce any side effects. A longer observation period is required to estimate the effects of long-term calcium lactate supplementation on lipid profiles of patients with hyperlipidaemia.

The study was financed by a grant of the President of the City of Lodz, Poland No G15. Calcium C preparation was obtained free of charge by Pharmaceutical Plan ‘Polfa’ in Lodz, Poland.

### References

7. Fleischman AL, Yacovitz H, Hayton T, et al. Long-term studies on the

### TABLE 2. MEAN VALUES OF SERUM LIPID CONCENTRATIONS IN PATIENTS AFTER THERAPY WITH CALCIUM PREPARATION AND IN HEALTHY SUBJECTS \(\pm SD; \text{MIN–MAX})

<table>
<thead>
<tr>
<th></th>
<th>Control group ((n = 22))</th>
<th>Before therapy</th>
<th>After therapy ((n = 21))</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC (mg/dl)</td>
<td>189.1 ± 15.16 (146.0–204.0)</td>
<td>249.8 ± 37.94 (203–338)</td>
<td>240.28 ± 35.44 ** (181–308)**</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>119.3 ± 12.11 (90.0–134.0)</td>
<td>165.95 ± 35.98 (106–261)</td>
<td>157.57 ± 31.79 (120–234)</td>
</tr>
<tr>
<td>HDL-C (mg/dl)</td>
<td>50.0 ± 10.54 (32.1–69.8)</td>
<td>53.78 ± 16.91 (34–90.3)</td>
<td>53.86 ± 17.62 (32.5–94.7)</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>100.1 ± 25.4 (52.0–147.0)</td>
<td>159.09 ± 111.22 (52–396)</td>
<td>146.8 ± 75.31 (40–381)</td>
</tr>
</tbody>
</table>

**p = 0.03 statistical comparison in relation to initial values before the therapy with calcium preparation.

### TABLE 3. MEAN VALUES OF TOTAL AND IONISED CALCIUM CONCENTRATION BEFORE AND AFTER THERAPY WITH CALCIUM PREPARATION \(\pm SD; \text{MIN–MAX})

<table>
<thead>
<tr>
<th></th>
<th>Control group ((n = 22))</th>
<th>Before therapy</th>
<th>After therapy ((n = 21))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ca (mg/dl)</td>
<td>9.3 ± 0.22 (8.84–9.96)</td>
<td>9.16 ± 1.07 (5–10.25)</td>
<td>8.97 ± 1.41 (4.87–10.63)</td>
</tr>
<tr>
<td>Ionised Ca (mg/dl)</td>
<td>4.34 ± 0.22 (4.06–4.91)</td>
<td>3.98 ± 0.22 (0.98–4.6)</td>
<td>4.27 ± 0.23 (3.91–4.78)</td>
</tr>
</tbody>
</table>

\(n = 5\), mean ± SD; min–max.

William Nelson ECG Quiz

Answer

The top tracing shows prominent Q waves in leads III and aVF, and a small one in lead II. If the patient were 66 years old, a diagnosis of inferior MI and precordial voltage of LVH would be appropriate – but at age 16? When the ECG was repeated a few hours later, the frontal leads were normal. Why? The upper tracing was due to a technical error. The left leg and arm electrodes had been reversed, changing the direction and polarity of the limb leads.